Rifamycin O

CAS : 14487-05-9

Ref. 3D-AR27729

Informations sur le produit

• Nom: Rifamycin O
• Synonymes: 4-O-(Carboxymethyl)-1-deoxy-1,4-dihydro-4-hydroxy-1-oxo-rifamycin gamma-lactoneNSC 182391, Rifamycin, 4-O-(carboxymethyl)-1-deoxy-1,4-dihydro-4-hydroxy-1-oxo-, γ-lactone, Spiro[1,3-dioxolane-2,9′(6′H)-[2,7](epoxypentadeca[1,11,13]trienimino)naphtho[2,1-b]furan], rifamycin deriv., Rifomycin O, Acetic acid, [(1,2,6,9-tetrahydro-5,9,17,19,21-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-1,6,11-trioxo-2,7-(epoxypentadeca[1,11,13]trienimino)naphtho[2,1-b]furan-9-yl)oxy]-, γ-lactone, 21-acetate, Spiro[1,3-dioxolane-2,9′(6′H)-[2,7](epoxypentadeca[1,11,13]trienimino)naphtho[2,1-b]furan]-1′,4,6′,11′(2′H)-tetrone, 5′,17′,19′,21′-tetrahydroxy-23′-methoxy-2′,4′,12′,16′,18′,20′,22′-heptamethyl-, 21′-acetate

Description

Rifamycin O inhibits the influenza virus by binding to effector proteins in the viral envelope. The monoclonal antibody is designed to bind to a protein target on the surface of cancer cells, which prevents them from proliferating. Rifamycin O has been shown to inhibit the growth of atherosclerotic lesions by targeting basic proteins on the surface of these lesions. This drug is not active against bowel disease or carcinoma cell lines. Rifamycin O has been shown to be effective in treating influenza when used with other drugs such as oseltamivir and zanamivir. It also appears to have a protective effect against obesity, which may be due to its ability to increase brown fat mass and decrease body mass index (BMI). Multivariate logistic regression analysis showed that rifamycin O use was associated with an increased risk for obesity.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 753.79 g/mol
• Formule: C₃₉H₄₇NO₁₄
• Degré de pureté: Min. 95%
• Couleur/Forme: Slightly Yellow Yellow Powder